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Abstract
The goal of this study was to assess the ability of iloprost, an orally active prostacyclin analog, to inhibit trans-
formed growth of human non–small cell lung cancer (NSCLC) and to define the mechanism of iloprost’s tumor
suppressive effects. In a panel of NSCLC cell lines, the ability of iloprost to inhibit transformed cell growth was
not correlated with the expression of the cell surface receptor for prostacyclin, but instead was correlated with the
presence of Frizzled 9 (Fzd 9) and the activation of peroxisome proliferator–activated receptor-γ (PPARγ). Silenc-
ing of Fzd 9 blocked PPARγ activation by iloprost, and expression of Fzd 9 in cells lacking the protein resulted in
iloprost’s activation of PPARγ and inhibition of transformed growth. Interestingly, soluble Frizzled-related protein-1,
a well-known inhibitor of Wnt/Fzd signaling, also blocked the effects of iloprost and Fzd 9. Moreover, mice treated
with iloprost had reduced lung tumors and increased Fzd 9 expression. These studies define a novel paradigm,
linking the eicosanoid pathway and Wnt signaling. In addition, these data also suggest that prostacyclin analogs
may represent a new class of therapeutic agents in the treatment of NSCLC where the restoration of noncanonical
Wnt signaling maybe important for the inhibition of transformed cell growth.
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Introduction
Lung cancer continues to be the leading cause of cancer death in
both men and women in the United States [1]. Most lung cancers
are diagnosed in former smokers, and to date, no effective treatment
has been discovered for nonsurgical lung cancer. The abysmal 5-year
lung cancer survival rates [2,3] underscore the need for better chemo-
theraputeic agents in the treatment of this disease.
Prostacyclin (PGI2) is a naturally occurring eicosanoid that pos-
sesses anti-inflammatory and antimetastatic properties [4]. Our lab-
oratory has demonstrated that mice with targeted overexpression of
prostacyclin synthase (PGIS) in the distal lung epithelia are protected
against lung tumor formation in response to chemical carcinogens or
cigarette smoke [5,6]. Supplementation with iloprost (a long-acting
oral PGI2 analog) also protects against chemically induced lung
carcinogenesis [7]. In fact, a recent phase 2 clinical trial provides
evidence that shows iloprost to be a very effective chemopreventive
agent in former smokers. However, the mechanism of iloprost’s anti-
tumorigenic effect is not well understood. Classically, the biological
effects of PGI2 are mediated through binding to a specific G protein–
coupled receptor (PTGIR), which signals through Gs resulting in the
elevation of cyclic adenosine monophosphate (cAMP) [8]; however,
mice overexpressing PGIS that lack PTGIR, the receptor for PGIS/
iloprost, are still protected against lung tumorigenesis, suggesting
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signaling through other receptors [7]. In addition, the efficacy of
prostacyclin analogs as chemotherapeutic agents in lung cancer has
not been examined. The goal of this study was to determine the
mechanism by which PGI2/iloprost affects the growth on human
non–small cell lung cancer (NSCLC) cells independent of the PTGIR
membrane receptor. We report that the ability of iloprost to inhibit
transformed growth is dependent on the expression of the Frizzled 9
(Fzd 9) receptor. Interestingly, iloprost, similar to Wnt 7a [9], also ac-
tivates peroxisome proliferator–activated receptor-γ (PPARγ) through
an ERK5-dependent pathway, suggesting that iloprost is able to mimic
the effects of Wnt 7a signaling and directly signals through Fzd 9. In
addition, this novel study is the first to identify an association between
the Wnt 7a and prostacyclin signaling pathways in NSCLC.
Materials and Methods
Materials, Cell Culture, and Retrovirus-Mediated
Gene Transfer
NSCLC lines ofH358, A549,H661,H1793,H2009,H157,H460,
H1334, H1703, and H2122 were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) at 37°C in an hu-
midified 5% CO2 incubator. RL-65, a spontaneously immortalized,
nontransformed lung epithelial cell, was cultured as previously described
by Bren-Mattison [10]. BEAS-2B, another immortalized, but non-
transformed lung epithelial cell line, was cultured in RPMI 1640 me-
dium supplemented with 10% FBS at 37°C in a humidified 5% CO2
incubator. Wi-38 was cultured in minimum essential medium with
Earle salts, nonessential amino acids, glutamine, and 1 mM sodium
pyruvate, supplemented with 10% FBS at 37°C in a humidified 5%
CO2 incubator. The H157-LNCX-LPCX and H157-Fzd-9 stable
clones have been previously described [11,12]. H157-PTGIR stable
clones were also created. The chemicals 10 μM iloprost (Cayman Chem,
Ann Arbor, MI), 10 μM ciglitazone (Cayman Chem), 10 μM PGE2
(Sigma, St. Louis, MO), 5 μM T0070907 (Cayman Chem), 25 μM
PD98059 (Sigma), and 5μMPD184352 (a generous gift fromDr. Philip
Cohen, University of Dundee, Scotland) were all applied daily for
each cell line used in our studies.
Quantitative Polymerase Chain Reaction
RNA was extracted from cultured cells with the RNeasy mini kit
(Qiagen, Inc, Valencia, CA). Total RNA that had been extracted
from the various cell lines. Aliquots of the RNA (10 μg) were con-
verted to complementary DNA with Superscript II (Invitrogen Corp,
Carlsbad, CA) and random hexamers according to the manufacturer’s
specifications. Primer sets for the quantitative reverse transcription–
polymerase chain reaction (RT-PCR) of human Fzd 9, human and
rat PTGIR, human PPARγ, human E-cadherin, and GAPDH were
designed. Rat IP/PTGIR: For 5′ TGT CAC ATG TAC CGC CAA
CAG AGA 3′, Rev 5′ ACC AGA ACT TGA GGC GTT GGA AGA
3′, Human IP/PTGIR: For 5′ GCC CTC CCC CTC TAC CAA 3′,
Rev 5′ TTT TCC AAT AAC TGT GGT TTT TGT G 3′, Human
PPARγ : For 5′ CATAAT GCC ATC AGG TTT GG 3′, Rev 5′ TCA
GCG GAC TCTGGATTC AG 3′,Human FZD9: For 5′ AAT TTT
CAT GTC ACT GGT GGT GG 3′, Rev 5′ TGC GGT AGC ACA
GGG TCT G 3′, Human E-cadherin: For 5′CGG GAA TGC AGT
TGAGGATC 3′, Rev 5′AGGATGGTGTAAGCGATGGC3′,Hu-
man GAPDH: For 5′ GGT GTC GCT GTT GAA GTC AGA G 3′,
Rev 5′ GCC AAA TAT GAT GAC ATC AAG AAG G 3′, Mouse
GAPDH: For 5′ CGT GGA GTC TAC TGG CGT CTT CAC 3′,
Rev 5′ CGG AGATGA CCC TTT TGG C 3′. The relative quantifi-
cation of real-time PCR data was determined by ΔΔC t. P ≤ .05 was
considered statistically significant by Student’s t-test.
Transfections and Reporter Luciferase Assays
The reporter plasmids (PPAR-RE, PDRE, PPARα, PPARγ-gal-4,
E-cadherin, Topflash, and MEF2C-gal 4), effector plasmids (Wnt 7a,
Fzd 9, wild-type PPARγ, wild-type PPARδ, wild-type PPARα, solu-
ble Frizzled-related protein-1 [sFRP1], β-catenin, PGIS, DN-MEK5,
and MKK5-alpha DD), and CMV-β-gal control plasmids were trans-
fected into cells using LipofectAmine reagent (Life Technologies,
Carlsbad, CA) as previously described [12]. Small interfering RNA
(siRNA) against Fzd 9 were purchased from Qiagen and used at con-
centrations between 50 and 75 nM. All cells were transfected with a
negative control siRNA tagged with a fluorescent marker (Qiagen),
which allows for an assessment of transfection efficiency.
Immunoblot Analysis
For immunoblot analysis of phospho-ERK5 (1:500; Cell Signaling,
Danvers, MA), total ERK5 (1:500; Cell Signaling), phospho-p44/
42 mitogen-activated protein kinase (1:1000; Cell Signaling), total
p44/42 MAP kinase (1:1000; Cell Signaling), E-cadherin (1:500; BD
Transduction Laboratories, San Jose, CA), β-actin (1:2000; Abcam,
Cambridge, MA), β-catenin (1:1000; BD Transduction Laboratories),
and Fzd 9 (1:400; Aviva Systems Biology, San Diego, CA), cell ex-
tracts were prepared in MAP kinase lysis buffer as previously de-
scribed [13].
Soft Agar Colony Formation
Measurement of anchorage-independent cell growth was performed
as previously described [13].
Cell Lines and cAMP Determination
Freshly isolated cell lines were resuspended in medium containing
10% fetal calf serum with 100 μM isobutylmethylxanthine (Sigma) ±
5 μM iloprost. The cells were incubated at 37°C for 45 minutes and
then washed three times quickly with cold phosphate-buffered saline.
The cell pellet was then lysed in cold 0.1 M HCl. Cellular cAMP
content was measured using the direct cAMP kit from Assay Designs
(Ann Arbor, MI). Results are reported as picomole of cAMP per mil-
ligram of protein.
Carcinogenesis Protocol and Iloprost Treatment of Mice
FVB/N mice 8 to 12 weeks of age were subjected to a single in-
traperitoneal injection of ethyl carbamate (Sigma) at a dose of 1 mg/g
mouse weight dissolved in normal saline. To determine the ability
of iloprost to prevent tumor formation, mice were fed antioxidant-
free chow (AIN-76A; Test Diet, Richmond, IN) containing 3%
ground iloprost tablets as described previously [5]. Iloprost or control
chow was maintained for 5 weeks after the initial urethane treatment.
Animals were killed 20 weeks later through pentobarbital over-
dose. Lungs were removed, and tumors were counted. Whole lungs
from control or iloprost-fed mice were snap-frozen, and whole-cell
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lysates were analyzed by Western analysis for Fzd 9 expression, as de-
scribed previously.
Statistical Analysis
Experimental results are represented in graphs as means ± SEM.
Data were analyzed by Student’s t-test for comparison of two data
sets using GraphPad Prism (San Diego, CA) with statistical signifi-
cance at P < .05 and is indicated by an asterisk (*).
Results
Anchorage-Independent Growth Is Inhibited in
Iloprost-Sensitive NSCLC
We assessed the effects of iloprost on anchorage-independent
growth in a panel of NSCLC cell lines. Measurement of soft agar
colony formation showed that iloprost was inhibitory by greater than
50% reduction in colony formation in some of the NSCLC tested
Figure 1. Iloprost inhibits anchorage-independent growth in some but not all NSCLC. (A) The indicated NSCLC cell lines were grown in
soft agar in the absence or presence of 10 μM iloprost. The colonies were incubated for several weeks and subsequently counted as
described in the Materials and Methods. Data are shown as mean of three independent experiments with the SEM indicated. (B) The cell
line A549 is shown to be iloprost-sensitive by soft agar, whereas H460 is seen to be an iloprost-insensitive cell line. (C) Activation of
PPARγ and E-cadherin is induced by iloprost. The indicated NSCLC cell lines were transiently transfected with PPAR-RE, along with
CMV-β-gal to normalize for transfection efficiency. After an overnight incubation, cells were exposed for 48 hours with 10 μM iloprost.
Extracts were prepared and promoter activity was determined as luciferase units normalized to CMV-β-gal. Results represent the mean of
three independent experiments with the SEM indicated. (D) The indicated NSCLC cell lines were transiently transfected with E-cadherin
reporter, along with CMV-β-gal to normalize for transfection efficiency and exposed for 48 hours with 10 μM iloprost. The PPARγ antag-
onist compound T0070907 reduces PPAR-RE activity induced by iloprost/Fzd 9. (E) The indicated cell lines were transiently transfected
with PPAR-RE, or empty vector, along with CMV-β-gal to normalize for transfection efficiency. After an overnight incubation, cells were
exposed for 48 hours with 10 μM iloprost and/or 5 μM T0070907.
246 Iloprost and Fzd 9 Inhibit NSCLC Cell Growth Tennis et al. Neoplasia Vol. 12, No. 3, 2010
(H358, A549,H661,H1793,H2009) but not in others (H157,H460,
H1334, H1703, H2122; Figure 1, A and B). These results suggest
that the cell lines that responded to iloprost express a receptor that
the nonresponding cell lines lack. Because several studies have dem-
onstrated frequent loss of both PGIS and PTGIR in lung cancer cell
lines and primary tumors [14–16], we measured PTGIR expression
by quantitative RT-PCR. Levels of PTGIR messenger RNA (mRNA)
were low or undetectable in all of the NSCLC cell lines tested com-
pared with several nontransformed lung epithelial cell lines (RL-65
and BEAS2B) and Wi-38, which was used as a positive control for
PTGIR (Figure W1A). The NSCLC cell lines were also evaluated for
their level of PPARγ expression and response to the specific PPARγ
agonist ciglitazone. All the cell lines had detectable PPARγ expression
as determined by quantitative RT-PCR (data not shown) and were re-
sponsive to ciglitazone as demonstrated by ciglitazone’s ability to activate
PPAR-RE (data not shown). To confirm the lack of functional PTGIR
expression, NSCLCs were stimulated with iloprost and increases in
cAMP were determined [7,17]. Iloprost failed to increase cAMP in
Figure 2. RNAi knockdown of Fzd 9 results in reduced PPARγ activity expression. (A) Total RNA purified from the indicated NSCLC cell
lines were submitted to quantitative RT-PCR using primers specific for Fzd 9 as described under Materials and Methods. The relative
mRNA abundance for Fzd 9 in the different samples was normalized to human GAPDHmeasured by RT-PCR in the same samples. Aliquots
of extracts containing equal protein as measured by the Bradford assay from the indicated cells were resolved by SDS-PAGE and immuno-
blotted with antibodies to Fzd 9 (100 kDa; Aviva Systems Biology). The filters were stripped and reimmunoblotted for β-catenin (80 kDa;
BD Transduction Laboratories) as a loading control. (B) The cell lines H157 and H1703 were transiently transfected with or without Fzd 9
and PPAR-RE along with CMV-β-gal to normalize for transfection efficiency. After an overnight incubation, cells were exposed for 48 hours
with 10 μM iloprost. (C) siRNA knockdown of Fzd 9 was performed as described in Materials and Methods on the indicated cell lines. Total
RNA purified from these cells were then submitted to quantitative RT-PCR using primers specific for Fzd 9 as previously described. The
relative mRNA abundance for Fzd 9 in the different samples was normalized to human GAPDH. (D) The indicated cell lines were transiently
transfected with PPAR-RE, along with CMV-β-gal to normalize for transfection efficiency. In addition, Fzd 9 was knocked down by transient
siRNA expression as indicated previously. After an overnight incubation, cells were exposed for 48 hours with 10 μM iloprost. (E) The
indicated cell line was transiently transfected with PPAR-RE, empty vector, or Fzd 9 along with CMV-β-gal to normalize for transfection
efficiency. After an overnight incubation, cells were exposed for 48 hours with 10 μM iloprost and/or 5 μM T0070907.
Neoplasia Vol. 12, No. 3, 2010 Iloprost and Fzd 9 Inhibit NSCLC Cell Growth Tennis et al. 247
any of the NSCLC lines examined (Figure W2B). As a positive control,
iloprost increased cAMP levels in H157 cells stably expressing PTGIR.
Iloprost Drives PPARγ Activation in a Subset of NSCLC
and Correlates to Anchorage-Independent Growth in
NSCLC Cell Lines
Data from other groups have shown that prostacylin analogs can
signal through PPARs [6,18,19]. We examined the ability of iloprost
to activate PPARα, PPARδ, or PPARγ in a panel of NSCLC cell
lines using a PPARα-, δ-, or γ-specific reporter linked to firefly lu-
ciferase. Iloprost increased PPAR-RE activity in H358, A549, H661,
H1793, and H2009, but gave no significant stimulation in H157,
H460, H1334, H1703, or H2122 (Figure 1C ). Interestingly, neither
PPARα nor PPARδ was activated by iloprost in the iloprost-sensitive
cell lines A549, H661, and H2009 (Figure W1C ). We also examined
E-cadherin, a downstream target of PPARγ [9,11], and discovered
that iloprost similarly increased both E-cadherin reporter activity
and protein expression (Figures 1D and W1B). Interestingly, iloprost
increased PPAR-RE activity in several cell lines, specifically A549,
H661, and RL-65, a nontransformed lung epithelial cell; this increase
was completely blocked by the specific PPARγ inhibitor, T0070907
(Figure 1E). Thus, activation of PPARγ and E-cadherin by iloprost cor-
related with the inhibition of anchorage-independent growth. Iloprost
did not stimulate the activation or reduction of the canonical β-catenin
pathway in any of the cell lines tested (data not shown).
The Presence of Fzd 9 Is Critical for Activation of PPARγ
by Iloprost
Given that most of the NSCLC cell lines lacked PTGIR (Fig-
ure W1A) and that iloprost did not increase PPARγ activity through
cAMP (Figure W2B), we hypothesized that iloprost-mediated activa-
tion of PPARγ might be mediated by another seven-transmembrane
spanning G protein–coupled receptor. We identified Fzd 9 as being a
potential candidate receptor mediating the effects of iloprost acti-
vation of PPARγ. Quantitative RT-PCR and immunoblot of Fzd 9
mRNA and protein were detected in all cell lines in which iloprost
activated PPAR-RE (H358, A549, H661, H1793, and H2009) but
was absent in cells that were unresponsive to iloprost (H157, H460,
H1334, H1703, and H2122; Figure 2A). Furthermore, quantitative
RT-PCR of these NSCLC cell lines showed that the H358, A549,
H661, H1793, and H2009 cells all expressed endogenous Fzd 9 but
no Wnt 7a [9,12]. H460, H1334, and H2122 expressed endogenous
Wnt 7a, but no Fzd 9 [9,12], and H157 and H1703 did not express
either Wnt 7a or Fzd 9 [9,12]. RL-65, a spontaneously immortalized,
Figure 3. Fzd 9 is necessary for the effects of iloprost reversal of anchorage independent growth. (A and B) A549 andH661 cells were grown in
soft agar exposed to siRNA knockdown of Fzd 9 or the PPARγ antagonist compound T0070907 at a concentration of 5 μM in the absence or
presence of 10 μM iloprost. The colonieswere incubated for several weeks and subsequently counted as previously described inMaterials and
Methods. (C and D) The H157 and H1703 cell lines encoding stable empty vector LPCX/LNCX or Fzd 9was grown in soft agar in the absence or
presenceof 10μMiloprost. Thecolonieswere incubated for severalweeks and subsequently counted throughMetamorph (Downingtown,PA).
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nontransformed lung epithelial cell, expressed both Wnt 7a and Fzd 9.
The expression of Fzd 9 or iloprost alone in both the H157 and
H1703 cells (these cells lacked endogenousWnt 7a, Fzd 9, and PTGIR)
did not affect basal PPAR-RE activity, but iloprost increased PPAR-RE
activity by approximately three-fold in the context of transient expres-
sion of Fzd 9 (Figure 2B).
We then examined the effect of silencing Fzd 9 in iloprost-sensitive
cell lines. Several NSCLC lines that expressed endogenous Fzd 9 but
lacked Wnt 7a and PTGIR (A549 and H661) were transfected with a
siRNA to Fzd 9, resulting in significantly decreased Fzd 9 expression
(Figures 2C and W1B). Silencing of Fzd 9 inhibited iloprost-mediated
activation of PPARγ in all cell lines tested (Figure 2D). Furthermore,
whereas iloprost was associated with decreased colony formation in the
cell lines with endogenous Fzd 9 expression (Figure 1A), siRNA
knockdown of Fzd 9 in theses cells resulted in no reduction of colony
number on soft agar assay in the presence of iloprost (Figure 3, A and
B). Conversely, we stably expressed Fzd 9 in the H157 and H1703 cell
lines that lacked endogenous Fzd 9, Wnt 7a, and PTGIR proteins. We
then examined the effects of the stable expression of Fzd 9 on colony
formation in soft agar in the H157 and H1703 cells. In the control
cells not expressing Fzd 9, iloprost did not reduce colony formation
(Figure 3, C and D). Consistent with previous findings [12], stable
expression of Fzd 9 alone in the H157 and H1703 cells did not affect
colony formation (Figure 3, C and D). However, iloprost inhibited
colony formation by approximately 90% in both the H157 and
H1703 cells stably expressing Fzd 9 (Figure 3, C and D). These data
indicate that iloprost and Fzd 9 have the ability to reverse anchorage-
independent growth and suggest a potential tumor suppressive effect
in NSCLC where iloprost can engage the Fzd 9 receptor.
Furthermore, the PPARγ antagonist compound T0070907 blocked
PPAR-RE activity in H157 cells expressing Fzd 9 exposed to iloprost
(Figure 2E). This effect was specific for Fzd 9 because overexpression
of other Fzd receptors in H157 cells (1, 2, 3, 4, 6, 7, 8, and 10) failed
to increase PPARγ activity (Figure 4B). Interestingly, the expression
Figure 4. Iloprost and Fzd 9 are specific in its activation of PPAR-RE and is not a generalized response to all prostaglandins, the effects
are also blocked by sFRP1. (A) Iloprost and Fzd 9 activate PPARγ. The A549 and H1703 cell lines were transiently transfected with the
PPAR-RE, sFRP1, Fzd 9, Wnt 7a, along with CMV-β-gal to normalize for transfection efficiency. After an overnight incubation, cells were
exposed for 48 hours with 10 μM iloprost. (B) The H157 cell line was transiently transfected with PPAR-RE, Fzds (1-10), along with CMV-
β-gal to normalize for transfection efficiency. After an overnight incubation, cells were exposed for 48 hours with 10 μM iloprost. (C) The
cell line H157 was transiently transfected with the reporter plasmid PPAR-RE and the effector plasmid PGIS, or Fzd 9, or exposed to
10 μM PGE2. Of note, CMV-β-gal was used to normalize for transfection efficiency. The cells were incubated for 48 hours, and luciferase
and β-galactosidase activities were measured. Data are presented as relative light units/milliunit of β-galactosidase activity. The results
showed that the coexpression of PGIS and Fzd 9 stimulated PPAR-RE activity but not the sole expression of PGIS, Fzd 9, or PGE2.
Furthermore, the coexpression of PGE2 and Fzd 9 similarly did not stimulate PPAR-RE activity.
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of Wnt 7a in the H157 cell line did not result in further stimulation of
PPAR-RE in the presence of iloprost (Figure W2A), supporting
the idea that both iloprost and Wnt 7a interact with Fzd 9 in a similar
fashion. To confirm that iloprost is mimicking the effects of PGI2,
activation of PPAR-RE was examined in H157 cells overexpressing
PGIS. Overexpression of PGIS alone had no effect on PPAR-RE ac-
tivity; however, transient expression of Fzd 9 significantly increased
PPAR-RE activity in cells overexpressing PGIS (Figure 4C ). Expression
of PGE2, a known protumorigenic prostacyclin family member, in the
context of Fzd 9 had no effect on PPAR-RE activity (Figure 4C), indi-
cating that this was not a generalized response to prostaglandins.
Expression of sFRP1 Blocks the Effect of Iloprost and Fzd 9
Activation of PPARγ
Soluble Frizzled-related proteins (sFRP) are known to block Wnt-
Fzd interaction, thereby turning off the Wnt signaling pathway [20].
We investigated whether sFRP1 could also block iloprost interaction
with Fzd 9. As a positive control, we coexpressed sFRP1 in the context of
NSCLC cell lines expressing Wnt 7a/Fzd 9 and, as predicted, Wnt 7a/
Fzd 9 was shown to have significantly reduced PPAR-RE activity in
those cells exposed to sFRP1 (Figure 4A). More interesting, however,
was that the expression of sFRP1 also blocked iloprost ability to activate
PPAR-RE in cells expressing Fzd 9 (Figure 4A). These results suggest
that there is a significant interaction between iloprost and Fzd 9.
Iloprost Activation of PPARγ Is Mediated through Activation
of ERK5
We sought to determine whether iloprost activation of PPARγ in-
volved ERK5 activation in NSCLC. Iloprost increased the MEF2C
reporter activity, a marker of MEK5 activation, and the phospho-
ERK5 levels five-fold in H157 cells stably expressing Fzd 9 but failed
to increase phospho-ERK5 in empty vector controls (Figure 5, A and
Figure 5. Iloprost and Fzd 9 induce phospho-ERK5 and MEF2C activity in NSCLC and is associated with PPARγ activity. (A) Retroviruses
encoding stable empty LNCX/LPCX or Fzd 9 were used to transduce the H157 NSCLC cell line as described previously in Materials and
Methods. Extracts were prepared from pooled G418 and puromycin-resistant cultures with MAPK lysis buffer, and aliquots containing
100 μg of protein were resolved on 10% polyacrylamide SDS gels, transferred to nitrocellulose, and probed with an antibody to phospho-
ERK5 (115 kDa; Cell Signaling). The filters were stripped and reimmunoblotted for total ERK5 (115 kDa; Cell Signaling), which was used
as a loading control protein. (B) The H157 cell line was transiently transfected with the MEF2C reporter, along with CMV-β-gal to normalize
for transfection efficiency. MKK5 alpha DD was used as a positive control plasmid. After an overnight incubation, cells were exposed for
48 hours with 10 μM iloprost. (C) Retroviruses encoding empty LNCX were used to transduce the A549 NSCLC cell line as described
previously in Materials and Methods. Extracts were prepared from pooled G418-resistant cultures with MAPK lysis buffer and aliquots
containing 100 μg of protein were resolved on 10% polyacrylamide SDS gels, transferred to nitrocellulose, and probed with an antibody
to phospho-ERK5 (115 kDa; Cell Signaling). The filters were stripped and reimmunoblotted for total ERK5 (115 kDa; Cell Signaling), which
was used as a loading control protein. (D) The A549 cell line was transiently transfected with the MEF2C reporter, along with CMV-β-gal to
normalize for transfection efficiency. MKK5 alpha DD was used as a positive control plasmid. After an overnight incubation, cells were
exposed for 48 hours with 10 μM iloprost.
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B); levels of total ERK5 were not changed (Figure 5A, bottom panels).
Similarly, A549 cells expressing endogenous Fzd 9 exposed to iloprost
showed a several fold increase in p-ERK5 expression relative to the
empty vector control cell lines by immunoblot and had increased in-
duction of the MEF2C reporter activity (Figure 5C). In all of these
cells, no significant changes in phospho-ERK1/2 levels were observed
(data not shown).
To test the functional role of ERK5 in activating PPARγ, cells
were treated with PD 98059, which selectively inhibits MEK1/2 and
MEK5. Exposure of H157 cells to 25 μM PD98059 blocked the
iloprost-mediated increase of PPAR-RE activity in cells expressing
Fzd 9 (Figure W2A). Treatment of H157 expressing Fzd 9 with PD
184352, which selectively inhibits MEK1/2 at the concentrations used,
had no effect on iloprost stimulation of PPAR-RE activity (Fig-
ureW2A). In addition, expression of DN-MEK5 had no effect on basal
PPAR-RE activity but inhibited the activation with iloprost in the set-
ting of Fzd 9 expression (data not shown).
Iloprost-Treated Mice Had Reduced Tumor Number and
Their Sensitivity Was Associated with the Presence of Fzd 9
To determine the effect of iloprost in an in vivo model, FVB/N
mice were maintained on control or iloprost chow for 5 weeks after
urethane injection with carcinogen ethyl carbamate (urethane). The
mice treated with 3% iloprost had decreased tumor numbers (3.4 ±
0.6 vs 7.8 ± 1.4 tumors/mouse, P < .0002) compared with the control
mice (Figure 6, A and C). The mice receiving 3% iloprost also had a
trend toward smaller tumors compared with the untreated mice.
Interestingly, the iloprost-treated mice had increased expression of
Fzd 9 as detected by immunoblot (Figure 6B) compared with the
untreated mice. Our in vitro experiments showed that the NSCLC
cell lines that did not express Fzd 9 did not seem to have increased
levels of Fzd 9 in response to iloprost (data not shown). Of note,
there was no difference in the protein expression level of Wnt 7a be-
tween the treated versus untreated mice (data not shown). These find-
ings suggest that the effects of iloprost’s ability to reduce tumor
number depend on Fzd 9 being present. The levels of PTGIR were
determined to be low in these mice after urethane exposure.
Discussion
The arachidonic acid pathway and its metabolites play a central role
in inflammation, pulmonary diseases, and cancer [21–23]. Elevated
levels of PGE2 have been observed in a variety of cancer, including
NSCLC, leading to the use of nonsteroidal anti-inflammatory drugs
as chemotherapeutic agents. In contrast, our data, as well as others,
demonstrate that the levels of PGIS, PGI2, and PTGIR are low in
most NSCLC [14–16], suggesting that both PGIS and its receptor
Figure 6. Iloprost treatment reduces tumor number and increases whole lung expression of Fzd 9. (A) Representative images of hema-
toxylin and eosin–stained urethane-treated lung tissue showing reduced tumor numbers and size in lungs from iloprost-fed mice (bot-
tom) compared with control chow-fed mice (top). The thick arrows indicate tumor(s) in the lung and the thin arrow points out the more
normal lung architecture in the mice receiving 3% iloprost chow. The right panels are higher-magnification images from the insets on
the left, demonstrating the effect of iloprost on individual adenoma size. Magnifications: ×100 (left) and ×400 (right). (B) Whole lung
tissue from urethane-treated mice fed normal or iloprost-impregnated chow (n = 4 each group) was snap-frozen, and whole-cell lysates
were analyzed by Western blot analysis for Fzd 9 expression. β-Actin was used as a loading control. (C) Lungs from mice described in
panel A were removed and tumors were counted. *P = .0002, different from control chow-fed mice.
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are downregulated. Our laboratory has demonstrated that increasing
PGI2 levels through targeted overexpression of PGIS or by adminis-
tration of prostacyclin analogs is chemoprotective against lung tumor
formation in mice [5]. The results from a large multicenter clinical
trial using iloprost in patients at risk for lung cancer seems to suggest
a very favorable outcome with the use of iloprost as a chemopreven-
tive agent in smokers. However, the chemotherapeutic potential of
prostacyclin has not been investigated. Previous data have indicated
that although expression of PGIS is low in most established human
lung tumors [14–16], a subset of patients with detectable expression
had a marked survival advantage [16]. Understanding the mecha-
nisms whereby PGI2 and its analogs inhibit cancer growth and pro-
gression and developing biomarkers to identify patients who may
respond to PGI2 therapy are therefore of critical importance.
From this study, we conclude that iloprost can inhibit transformed
growth of a subset of NSCLC through the activation of PPARγ
through an independent membrane receptor mechanism involving
the Fzd 9 pathway. Work from our laboratory and by other investi-
gators have demonstrated that PPARγ activation in NSCLC leads to
growth inhibition, promotion of apoptosis, inhibition of invasive-
ness, and metastasis [10,11]. Moreover, PPARδ has been shown to
enhance tumorigenesis in lung epithelial cells [24]. Therefore, defin-
ing the factors that are necessary for iloprost to activate PPARγ will
be critical in developing this agent as a chemotherapeutic drug. Our
data indicate that the expression of the G protein–coupled receptor,
Fzd 9 [25–29], determines the ability of iloprost to activate PPARγ
and inhibit cancer growth in NSCLC cells. Silencing of Fzd 9 expres-
sion in NSCLC cell lines that express the protein blocks the ability of
iloprost to activate PPARγ and renders the cells insensitive to growth
inhibition by iloprost (Figure 3, A and B). Conversely, expressing Fzd 9
in NSCLC cell lines lacking endogenous Fzd 9 seemed to sensitize the
cells to growth inhibition by iloprost through a PPARγ-dependent
pathway (Figure 3, C and D). Although Fzd 9 has been shown to
be a receptor for Wnt 7a, and the engagement of this pathway inhibits
transformed growth through ERK5-dependent activation of PPARγ
[9,12], there is no existing soluble Wnt 7a protein that could be used
for clinical trial. A recent study has demonstrated that prostacyclin ana-
logs activate PPARγ through the prostacyclin receptor PTGIR [30].
Our data, however, do not support a role for PTGIR in mediating
the effects of iloprost in NSCLC. All of the NSCLCs we have exam-
ined have very low to undetectable levels of PTGIR mRNA, and ad-
ministration of iloprost failed to increase cAMP, an effector pathway
for PTGIR (Figures W1A and W2B). Although we have not directly
demonstrated iloprost binding to Fzd 9 in this current study, our data
strongly suggest that this may indeed be the case as shown by sFRP1’s
ability to block iloprost/Fzd 9 signaling. This study is the first to
demonstrate such an association between the Wnt and prostacyclin
pathways. Iloprost stimulation in Fzd 9–positive cells results in the ac-
tivation of ERK5 (Figure 5), as occurs with Wnt 7a stimulation, and
this activation is critical for subsequent PPARγ activation.
Our data as well as others’ raise the possibility that activators of
PPARγ may represent an effective treatment of patients with lung
cancer [9,31,32]. Thiazolinediones have been shown to reduce the
risk of lung cancer in clinical trials [33], and activation of PPARγ
in NSCLC cell lines has been shown to reverse the transformed pheno-
type in several studies [10,11,34–40]. Engagement of Fzd 9 by its li-
gand Wnt 7a inhibits growth of NSCLC through activation of PPARγ
[9]. Whereas Wnt 7a recombinant therapy seems attractive, there is no
recombinant Wnt 7a protein available for clinical use at this time.
Studies using epidermal growth factor receptor inhibitors are focused
on developing biomarkers to predict which patients will best respond
to these agents. This study indicates that a similar strategy can be used
to predict responders to iloprost by assessing their Fzd 9 status. Future
clinical chemoprevention trials should determine if the expression of
Fzd 9 is associated with the effects of iloprost on progression of dys-
plasias. However, our data indicate that Fzd 9 status may also define
the utility of prostacyclin analogs as chemotherapeutic agents. Clinical
trials to examine this seem to be warranted.
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Figure W1. siRNA reduces E-cadherin expression and PTGIR is absent in NSCLC. (A) Total RNA purified from the indicated NSCLC cell
lines were submitted to quantitative RT-PCR using primers specific for PTGIR as described under Materials and Methods. The relative
mRNA abundance for PTGIR in the different samples was normalized to human GAPDH measured by RT-PCR in the same samples.
(B) E-cadherin protein expression by iloprost and Fzd 9 are reduced by Fzd 9 siRNA knockdown. Aliquots of extracts containing equal
protein as measured by the Bradford assay from the indicated cells were resolved by SDS-PAGE and immunoblotted with antibodies to
E-cadherin (125 kDa; BD Transduction Laboratories) and Fzd 9 (100 kDa; Aviva Systems Biology). The filters were stripped and reim-
munoblotted for β-actin (47 kDa; Abcam) as a loading control. (C) The indicated NSCLC cell lines were transiently transfected with PDRE
or PPARα-luc, along with CMV-β-gal to normalize for transfection efficiency. After an overnight incubation, cells were exposed for
48 hours with 10 μM iloprost. Extracts were prepared, and promoter activity was determined as luciferase units normalized to CMV-
β-gal. Results represent the mean of three independent experiments with the SEM indicated.
Figure W2. Iloprost and Fzd 9 do not activate PPARγ through activation of cAMP and PD98059 blocks its effect. (A) The ERK pathway
inhibitor PD98059 significantly reduces PPAR-RE activity induced by both iloprost and Fzd 9 or Wnt 7a/Fzd 9, but the MEK1/2 inhibitor
PD184352 has no affect the PPAR-RE activity induced by either iloprost and Fzd 9 or Wnt 7a/Fzd 9. The H157 cell line was transiently
transfected with PPAR-RE, empty vector pCDNA3, Wnt 7a, Fzd 9, or both Wnt 7a/Fzd 9, along with CMV-β-gal to normalize for trans-
fection efficiency. After an overnight incubation, cells were exposed for 48 hours with either 25 μM PD98059, 5 μM PD184352, and/or
iloprost 10 μM. (B) The indicated cell lines were exposed to 10 μM of iloprost, and then cellular cAMP content was measured using the
direct cAMP kit from Assay Designs. Results are reported as picomole of cAMP per milligram of protein. The H157 cell line encoding
empty vector LPCX, LPCX-Fzd 9, or LPCX-PTGIR were exposed to iloprost 5 μM and measured for direct cAMP kit from Assay Designs.
Results are reported as picomole of cAMP per milligram of protein.
